About Us

Dr. Verden recently earned his PhD in Neuroscience at the University of Colorado Anschutz Medical Campus. His experience in researching topics such as cell biology and neurodegeneration combined with his science communication and network management skills make him uniquely suited for this new role at KIF1A.ORG.

Luke Rosen and Sally Jackson founded KIF1A.ORG in 2016 following their daughter Susannah’s KIF1A diagnosis. In 2017 Luke left his career in film and television to accelerate discovery of treatment for Susannah and children like her. With a focus on research strategy and outcome measures, Luke works to educate and activate families affected by rare genetic diseases. His mission is to accelerate biotech innovation and forge efficient collaborations within the scientific community to rapidly discover treatment for KIF1A Associated Neurological Disorder. Working closely with all stakeholders, Luke makes sure every family is active in discovery, from pre-clinical research through clinical trial readiness. Luke helps drive our mission to urgently find treatment for children living with KIF1A Associated Neurological Disorder.

After an engaging and enlightening summer 2021 internship with KIF1A.ORG, Michelle has officially joined KIF1A.ORG’s team as the Therapeutic Development Associate, where she will help the team accelerate treatment for KAND. Michelle is a current student in the MA in Biotechnology program at Columbia University. She graduated from NYU Stern with a B.S. in Business (concentrations in Finance and Global Business) and a minor in Genetics. Subsequently, she worked in healthcare banking for 5 years. Michelle is passionate about breaking down human-made barriers to treatment in order to ensure equitable access to care.